This database contains 542 studies, archived under the term: "middle aged"
Click here to filter this large number of results.
Cognitive decline from estimated premorbid status predicts neurodegeneration in Alzheimer’s disease
This study investigated the relationship between premorbid and current cognitive function with respect to the clinical features of patients with various types of neurodegeneration in the form of Alzheimer’s disease (AD), mild cognitive impairment (MCI), and subjective cognitive impairment (SCI), as compared with a healthy control group (C). Clinical features (MMSE, cognitive and depressive symptoms), […]
Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer’s disease: a 26-week, open-label, prospective trial (Study ENA713B US32)
Olin, Jason T.,
Bhatnagar, Vinod,
Reyes, Patricio,
Koumaras, Barbara,
Meng, Xiangyi,
Brannan, Stephen
Objective: Rivastigmine, a dual cholinesterase inhibitor (ChEI), is widely approved for the symptomatic treatment of both mild-to-moderate Alzheimer’s disease (AD) and Parkinson’s disease dementia. Orally administered ChEIs may be associated with gastrointestinal (GI) side effects and add-on therapy with memantine, an N-methyl-d-aspartate receptor antagonist, approved for moderate-to-severe AD, may ameliorate such side effects. This was […]
Urine neural thread protein measurements in Alzheimer disease
Objectives: Neural thread protein (NTP), a membrane-associated phosphoprotein, was selectively elevated in the urine of patients with Alzheimer disease (AD). To demonstrate the potential utility of urine NTP assays for the diagnosis of AD, we performed this study.; Design: A prospective blinded multicentered study.; Participants: Individuals diagnosed as having probable AD (n = 49), Parkinson’s […]
Visual evoked potentials to pattern, motion and cognitive stimuli in Alzheimer’s disease
Kubová, Z.,
Kremlácek, J.,
Valis, M.,
Langrová, J.,
Szanyi, J.,
Vít, F.,
Kuba, M.
The aim of our study was to verify reported visual dysfunctions of patients with Alzheimer disease with the use of several variants of VEPs and visual ERPs and to learn whether these methods can be useful in diagnostics of AD. We tested 15 patients (6 women and 9 men, aged from 58 to 87) with […]
Errorless practice as a possible adjuvant to donepezil in Alzheimer’s disease
Rothi, Leslie J. Gonzalez,
Fuller, Renee,
Leon, Susan A.,
Kendall, Diane,
Moore, Anna,
Wu, Samuel S.,
Crosson, Bruce,
Heilman, Kenneth M.,
Nadeau, Stephen E.
Six individuals with probable Alzheimer’s disease (AD) participated in a phase 1 study employing a repeated measures, parallel baseline design testing the hypothesis that error-free experience during word production practice combined with an acetyl cholinesterase inhibitor would improve confrontation naming ability. While acetyl cholinesterase inhibitors are safe and delay cognition decline associated with AD, improvement […]
Lithium trial in Alzheimer’s disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study
Hampel, Harald,
Ewers, Michael,
Bürger, Katharina,
Annas, Peter,
Mörtberg, Anette,
Bogstedt, Anna,
Frölich, Lutz,
Schröder, Johannes,
Schönknecht, Peter,
Riepe, Matthias W.,
Kraft, Inga,
Gasser, Thomas,
Leyhe, Thomas,
Möller, Hans-Jürgen,
Kurz, Alexander,
Basun, Hans
Objective: Lithium, a first-line drug for the treatment of bipolar depression, has recently been shown to regulate glycogen synthase kinase-3 (GSK-3), a kinase that is involved in the phosphorylation of the tau protein. Since hyperphosphorylation of tau is a core pathological feature in Alzheimer’s disease, lithium-induced inhibition of GSK-3 activity may have therapeutic effects in […]
Effect of tramiprosate in patients with mild-to-moderate Alzheimer’s disease: exploratory analyses of the MRI sub-group of the Alphase study
Gauthier, S.,
Aisen, P. S.,
Ferris, S. H.,
Saumier, D.,
Duong, A.,
Haine, D.,
Garceau, D.,
Suhy, J.,
Oh, J.,
Lau, W.,
Sampalis, J.
Objectives: The efficacy, safety and disease-modification of tramiprosate (homotaurine)were investigated in a recently completed large-scale Phase III clinical study in patients with mild to moderate Alzheimer’s disease (AD), the Alphase study. Disease-modification was assessed using longitudinal volumetric MRI (vMRI) measurements of the hippocampus in a subgroup of patients. The present study describes the vMRI, cognitive […]
Ginkgo biloba extract EGb 761(R), donepezil or both combined in the treatment of Alzheimer’s disease with neuropsychiatric features: a randomised, double-blind, exploratory trial
Yancheva, S.,
Ihl, R.,
Nikolova, G.,
Panayotov, P.,
Schlaefke, S.,
Hoerr, R.
Objective: This randomised, double-blind exploratory trial was undertaken to compare treatment effects and tolerability of EGb 761(R), donepezil and combined treatment in patients with AD and neuropsychiatric features.; Method: We enrolled 96 outpatients, aged 50 years or above, who met the NINCDS/ADRDA criteria for probable AD, scored below 36 on the TE4D, a screening test […]
Rosiglitazone monotherapy in mild-to-moderate Alzheimer’s disease: results from a randomized, double-blind, placebo-controlled phase III study
Gold, Michael,
Alderton, Claire,
Zvartau-Hind, Marina,
Egginton, Sally,
Saunders, Ann M.,
Irizarry, Michael,
Craft, Suzanne,
Landreth, Gary,
Linnamägi, Ulla,
Sawchak, Sharon
Background/aims: A phase II study of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone extended release (RSG XR) in mild-to-moderate Alzheimer’s disease (AD) detected a treatment benefit to cognition in apolipoprotein E(APOE)-ε4-negative subjects. The current phase III study with prospective stratification by APOE genotype was conducted to confirm the efficacy and safety of RSG XR in mild-to-moderate […]